Compare Incept Biosystems vs Inotek Pharmaceuticals
Customers evaluate the quality of Incept Biosystems's products using the following success metrics.
Incept Biosystems is 19 yrs old and is based in United States.
Incept BioSystems aims to develop nanoscale technologies that provide cell biologists the ability to obtain high value data about cell growth and behavior. Their technologies were developed to improve the in vitro manipulation, performance and viability for Premium Cell Management applications. On January 12, 2011, Incept BioSystems was acquired by ORIGIO. The terms of the transaction were not disclosed.
Inotek Pharmaceuticals is 28 yrs old and is based in United States.
Inotek Pharmaceuticals is a biotechnology company focused on the discovery and development of drugs to address serious diseases of the eye. Inotek scientists have identified a deep pipeline of drug candidates to ameliorate inflammation, ischemia-reperfusion injury, and oxidative stress, which are key targets for drugs to treat Glaucoma, Ocular Hypertension, Age-related Macular Degeneration and Retinal Neuropathies. The Company's lead program, trabodenoson (INO-8875) is a highly selective adenosine mimetic that targets the A1 sub-receptor. Trabodenoson brings a novel and elegant mechanism of action for the treatment of elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. This new approach to lowering IOP augments the natural process that healthy eyes use to allow excess fluid to drain from the eye through the trabecular meshwork, and makes trabodenoson, if ultimately approved by health authorities worldwide, a valuable tool that ophthalmologist can use alone or in conjunction with any of the available medicines for glaucoma. The candidate has completed a Phase 1 and Phase2 clinical trials in patients and is currently being evaluated in a multiple-dose late Phase 2 trial. In the completed clinical trials, trabodenoson was well tolerated and was shown to significantly reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Why They Buy
Information not available because Incept Biosystems has not claimed their profile.
Work for Incept Biosystems? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Incept Biosystems?
Claim your profile now.
Information not available because Inotek Pharmaceuticals has not claimed their profile.
Work for Inotek Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Inotek Pharmaceuticals?
Claim your profile now.